Efficacy of Sulfamethoxypyridazine in a Murine Model of Pneumocystis Carinii Pneumonia

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1998 Apr 29

PMID 9559812

Citations 4

Authors

M S Bartlett

M M SHAW

J W Smith

S R Meshnick

Affiliations

Soon will be listed here.

Abstract

Sulfamethoxazole is the component of co-trimoxazole responsible for its efficacy against Pneumocystis carinii pneumonia, but this drug is associated with frequent adverse effects. Sulfamethoxypyridazine is significantly more effective than sulfamethoxazole against a murine model of P. carinii and might be a candidate for testing in infected patients.

Citing Articles

Novel Ring Systems: Spiro[Cycloalkane] Derivatives of Triazolo- and Tetrazolo-Pyridazines.

Sepsey Fur C, Riszter G, Szigetvari A, Dekany M, Keglevich G, Hazai L Molecules. 2021; 26(8).

PMID: 33917797 PMC: 8068119. DOI: 10.3390/molecules26082140.

Bladder catheterization increases susceptibility to infection that can be prevented by prophylactic antibiotic treatment.

Rousseau M, Goh H, Holec S, Albert M, Williams R, Ingersoll M JCI Insight. 2016; 1(15):e88178.

PMID: 27699248 PMC: 5033754. DOI: 10.1172/jci.insight.88178.

Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Iliades P, Meshnick S, Macreadie I Antimicrob Agents Chemother. 2005; 49(2):741-8.

PMID: 15673759 PMC: 547354. DOI: 10.1128/AAC.49.2.741-748.2005.

In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.

Afeltra J, Meis J, Vitale R, Mouton J, Verweij P Antimicrob Agents Chemother. 2002; 46(6):2029-31.

PMID: 12019133 PMC: 127271. DOI: 10.1128/AAC.46.6.2029-2031.2002.

References

Lane B, Ast J, Hossler P, Mindell D, Bartlett M, Smith J . Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis. 1997; 175(2):482-5. DOI: 10.1093/infdis/175.2.482. View

Funk K . [Pharmacokinetic model studies on the rat. The single-chamber model of the organism]. Acta Biol Med Ger. 1970; 25(1):151-60. View

Rallison M, OBrien J, GOOD R . Severe reactions to long-acting sulfonamides. Erythema multiforme exudativum and lupus erythematosus following administration of sulfamethoxypyridazine and sulfadimethoxine. Pediatrics. 1961; 28:908-17. View

Simonds R, Hughes W, Feinberg J, Navin T . Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995; 21 Suppl 1:S44-8. DOI: 10.1093/clinids/21.supplement_1.s44. View

Walzer P, Foy J, Steele P, Kim C, White M, Klein R . Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992; 36(9):1935-42. PMC: 192212. DOI: 10.1128/AAC.36.9.1935. View

Hong Y, Hossler P, Bartlett M, Queener S, Smith J, Meshnick S . Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo. J Eukaryot Microbiol. 1996; 43(5):40S. DOI: 10.1111/j.1550-7408.1996.tb04976.x. View

Bartlett M, Queener S, Durkin M, Shaw M, Smith J . Inoculated mouse model of Pneumocystis carinii infection. Diagn Microbiol Infect Dis. 1992; 15(2):129-34. DOI: 10.1016/0732-8893(92)90036-s. View

Kunz S, Junker U, Blaser J, Joos B, Meyer B, Zak O . The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. J Antimicrob Chemother. 1995; 36(1):137-55. DOI: 10.1093/jac/36.1.137. View

Cortese L, Soucy D, Endy T . Trimethoprim/sulfamethoxazole desensitization. Ann Pharmacother. 1996; 30(2):184-6. DOI: 10.1177/106002809603000214. View

10.

Bjorkman A, Phillips-Howard P . Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ. 1991; 69(3):297-304. PMC: 2393107. View

11.

SALVAGGIO J, Gonzalez F . Severe toxic reactions associated with sulfamethoxypyridazine (kynex). Ann Intern Med. 1959; 51(1):60-7. DOI: 10.7326/0003-4819-51-1-60. View

12.

Hughes W, Killmar J . Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1996; 40(4):962-5. PMC: 163239. DOI: 10.1128/AAC.40.4.962. View

13.

Hong Y, Hossler P, Calhoun D, Meshnick S . Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995; 39(8):1756-63. PMC: 162822. DOI: 10.1128/AAC.39.8.1756. View

14.

Cribb A, Lee B, Trepanier L, Spielberg S . Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996; 15(1):9-50. View

15.

Hoover D, Saah A, Bacellar H, Phair J, Detels R, Anderson R . Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993; 329(26):1922-6. DOI: 10.1056/NEJM199312233292604. View